Screener
Moderna MRNA Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Moderna in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.
The source filing: Moderna’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001682852-26-000060
| U.S. treasury notes | (3) | 960 | (2) | 236 | (5) | 1,196 | ||||||
| Corporate debt securities | (6) | 1,562 | — | 35 | (6) | 1,597 | ||||||
| Government debt securities | — | 56 | — | — | — | 56 | ||||||
| Total | $ | $(9) | $ | $3,601 | $ | $(2) | $ | $271 | $ | $(11) | $ | $3,872 |
| As of December 31, 2025: | ||||||||||||
| U.S. treasury bills | $ | — | $ | $111 | $ | — | $ | — | $ | — | $ | $111 |
| U.S. treasury notes | (1) | 176 | (2) | 235 | (3) | 411 | ||||||
| Corporate debt securities | — | 608 | (1) | 40 | (1) | 648 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Moderna's cash, cash equivalents, and marketable securities?
- Moderna (MRNA) reported cash, cash equivalents, and marketable securities of $11M in Q1 2026.
- How has Moderna's cash, cash equivalents, and marketable securities changed year-over-year?
- Moderna's cash, cash equivalents, and marketable securities decreased by 15.4% year-over-year, from $13M to $11M.
- What is the long-term trend for Moderna's cash, cash equivalents, and marketable securities?
- Over 4 years (2021 to 2025), Moderna's cash, cash equivalents, and marketable securities has grown at a -47.3% compound annual growth rate (CAGR), from $52M to $4M.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.
Ask your AI about Moderna's cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude